Latest H5N1 clinical trials Stories

Ready to Manufacture a Vaccine for the H7N9 Influenza Virus MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine. It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary,...

All 3 configurations of adjuvant and route of administration exceeded the 3 CHMP criteria IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs),...

PISCATAWAY, N.J., April 11, 2013 /PRNewswire/ -- This week the World Health Organization reported three cases in which humans were infected with Avian Influenza A (H7N9) Virus in China. These are the first reports of the H7N9 strain infecting humans. Currently, it is unclear whether or not the virus can be spread via human-to-human contact, however genetic sequences for the virus have been published, and the Center for Disease Control has reported the start of vaccine development for...

LONDON, April 9, 2013 /PRNewswire/ -- Bioradar UK Ltd and Replikins Ltd announced today that a new completely synthetic H7N9 Replikins Vaccine is ready for testing. The news comes on the heels of four new cases of avian flu (H7N9) reported in China, bringing the total to 28 cases, 8 of whom have died from the virus. The new vaccine is produced without any biological substances and will be used without adjuvants, similar to the H5N1 Synthetic Replikins Vaccine which was found...

Team will develop and manufacture GSK's next generation influenza vaccines to protect the nation against global pandemics AUSTIN, Texas and PHILADELPHIA, March 26, 2013 /PRNewswire/ -- GlaxoSmithKline plc (GSK) and The Texas A&M University System announced today that the U.S. Department of Health and Human Services (DHHS) has approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and...

- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4% BEIJING, March 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD"). The primary objective of the study was to...

A candidate dengue vaccine developed by scientists at the National Institutes of Health (NIH) has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results were published online on January 17 in the Journal of Infectious Diseases. Dengue fever, prevalent in many tropical and subtropical...

Lee Rannals for redOrbit.com – Your Universe Online A new flu vaccine won regulatory approval on Wednesday and its limited supplies are expected to be available this winter. Protein Sciences won the approval for Flublok, which is made with a process that does not require the virus to be grown in chicken eggs. “This approval represents a technological advance in the manufacturing of an influenza vaccine,” Dr. Karen Midthun, a senior official at the U.S. Food and Drug...

MERIDEN, Conn., Jan. 16, 2013 /PRNewswire/ -- The U.S. FDA approved Flublok for people 18-49 years old - making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is expected later in 2013. Flublok features: First influenza vaccine made without the use of live influenza virus First egg-free influenza vaccine Highly purified without preservatives (thimerosal), antibiotics or adjuvants Three times the active...

BLUE BELL, Pa., Dec. 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported interim results of a phase I trial that showed that a single dose of its H1N1 universal SynCon® flu vaccine followed with a dose of a seasonal flu vaccine generated protective immune responses in 40% of trial subjects compared with a 20% response rate in elderly patients who received the seasonal flu vaccine alone. This interim data is a significant step in developing a more...